Clinical Trial Update: A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describes a study of QL1706 combined with albumin-bound paclitaxel and bevacizumab for platinum-resistant recurrent ovarian canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Abraxane (albumin-bound paclitaxel) (paclitaxel protein-bound albumin)
• Bevacizumab (bevacizumab)
• QL1706

Snippet

Sponsor: West China Second University Hospital | Conditions: Platinum-resistant Recurrent Ovarian Cancer | Phase 2 | Status: NOT_YET_RECRUITING